Omega Fund Management, LLC holds a concentrated book of 10 stocks worth $163.1M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they trimmed Kestra Medical Technologies. Their largest long position is Bicara Therapeutics Inc at 29% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Omega Fund Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 11 / 10 | $101.0M |
| MORGAN STANLEY | 11 / 10 | $81.8M |
| BARCLAYS PLC | 11 / 10 | $7.4M |
| BNP PARIBAS FINANCIAL MARKETS | 11 / 10 | $6.4M |
| WELLS FARGO & COMPANY/MN | 11 / 10 | $4.2M |
| FMR LLC | 10 / 10 | $600.4M |
| BlackRock, Inc. | 10 / 10 | $524.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 10 / 10 | $281.3M |
Ranked by the share of each fund's own book sitting in the names it shares with Omega Fund Management, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. Common Stock | $47.6M | 2.39M | 29.2% | ▲+8.5% Added · +188K sh | |
| 2 | Nuvation Bio Inc. Common Stock Class A | $34.7M | 8.08M | 21.2% | —Held | |
| 3 | BridgeBio Oncology Therapeutics Inc. Common Stock | $29.4M | 3.29M | 18.0% | —Held | |
| 4 | Kestra Med Technologies Ltd Common Stock | $20.4M | 1.02M | 12.5% | ▼−26% Reduced · −351K sh | |
| 5 | Beta Bionics Inc. Common Stock | $13.2M | 1.32M | 8.1% | —Held | |
| 6 | enGene Holdings Inc. Common Stock | $6.0M | 876.4K | 3.7% | —Held | |
| 7 | Alumis Inc. Common Stock | $5.3M | 241.3K | 3.3% | ▼−63% Reduced · −412K sh | |
| 8 | Sana Biotechnology, Inc. Common Stock | $2.4M | 843.8K | 1.5% | —Held | |
| 9 | ImageneBio, Inc. Common Stock | $2.3M | 455.4K | 1.4% | —Held | |
| 10 | Replimune Group Common Stock | $1.9M | 248.7K | 1.2% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1637359/holdings"
Use Arkolith to show Omega Fund Management, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.